Intermediate and high dose Ara-C and m-AMSA for remission induction and consolidation treatment of patients with acute myeloid leukemia: an EORTC leukemia cooperative group phase II study

This publication has 12 references indexed in Scilit:

• Results of induction and consolidation treatment with intermediate and high‐dose cytosine arabinoside and m‐Amsa of patients with poor‐risk acute myelogeneous leukaemia
  European Journal of Haematology, 1988
• RESULTS OF INDUCTION AND CONSOLIDATION TREATMENT WITH INTERMEDIATE AND HIGH‐DOSE ARA‐C AND m‐AMSA CONTAINING REGIMENS IN PATIENTS WITH PRIMARILY FAILED OR RELAPSED ACUTE LEUKEMIA AND NON‐HODGKIN'S LYMPHOMA
  Scandinavian Journal of Haematology, 1986
• High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia.
  Journal of Clinical Oncology, 1985
• High-dose cytosine arabinoside and m-AMSA is effective therapy in relapsed acute nonlymphocytic leukemia.
  Journal of Clinical Oncology, 1984
• The use of intermediate dose cytosine arabinoside (ID Ara‐C) in the treatment of acute non‐lymphocytic leukaemia in relapse
  British Journal of Haematology, 1984
• High-dose cytosine arabinoside therapy for refractory leukemia
  Blood, 1983
• HIGH-DOSE CYTOSINE-ARABINOSIDE THERAPY FOR REFRACTORY LEUKEMIA
  1983
• EXPERIENCE WITH INTERMEDIATE-DOSE AND HIGH-DOSE CYTOSINE-ARABINOSIDE IN RELAPSED AND REFRACTORY ACUTE-LEUKEMIA
  1983
• A PILOT-STUDY OF HIGH-DOSE 1-BETA-D-ARABINOFURANOSYLCYTOSINE FOR ACUTE-LEUKEMIA AND REFRACTORY LYMPHOMA - CLINICAL-RESPONSE AND PHARMACOLOGY
  1982
• High dose cytosine arabinoside (HDARAC) in refractory acute leukemia
  Cancer, 1979